REDMOD, RASONQUE mark pancreatic-cancer breakthrough

The compelling story is convergence: better detection may create the window in which better treatments can actually matter.

• –REDMOD achieved 73% sensitivity and 81.1% specificity, outperforming radiologists particularly more than two years before diagnosis.
• –The model extracts subtle radiomic patterns invisible to routine human review, showing how medical AI can extend existing imaging infrastructure.
• –REDMOD remains retrospective and requires prospective validation; false positives and clinical follow-up could limit real-world impact.
• –RASONQUE targets RAS-driven tumors and is approved specifically for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy.
• –Together, the advances point toward a screening-to-treatment pipeline—but only if early AI alerts reliably trigger actionable care.